Sai-Kiang Lim and group members transferred to A*STAR’s Institute of Molecular & Cell Biology on the 1st April 2020.
The major focus of our present research program is to characterize exosomes and other classes of EVs that are secreted by MSCs, and to elucidate the molecular processes for their biogenesis and uptake. We are also investigating several disease indications for MSC exosomes such as acute and chronic myocardial infarction, severe genetic skin diseases e.g. recessive dystrophic epidermolysis bullosa, severe immune diseases e.g. steroid-refractory graft versus host disease, drug induced liver toxicity. This research has led to the development of several proprietary technological platforms for stem cell or synthetic EV-based therapeutics and diagnostics. Since its inception at IMB in 2007, the lab has generated >80 publications, and > 51 granted and 10 pending patents. To capitalise on these promising results, we have set up extensive partnerships with industry entities and are in the process of bringing to market EV-based biologics.
The current lab was established in 2007 with a research focus on extracellular vesicles (EVs) from stem cells and synthetic EVs for the development of diagnostics and therapeutics.
The lab was the first to demonstrate that mesenchymal stem cells (MSCs) secrete therapeutic exosomes, a class of EVs. Since then, many of the reported therapeutic efficacies of MSCs for a wide spectrum of diseases were found to be underpinned by EVs.
The group research program is a highly collaborative, multi-disciplinary endeavour that comprises of local and international basic, clinical and industrial research groups. Our group is highly involved in the activities of Society for Clinical Research and Translation of Extracellular Vesicles Singapore (SOCRATES) and International Society of Extracellular Vesicles (ISEV) to facilitate research communication and collaboration to develop the therapeutic potential of EVs.
For more information, please contact Lim Sai Kiang.